

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. PLEASE REFER TO "IMPORTANT INFORMATION" AT THE END OF THE PRESS RELEASE.

Press release
May 18 2022

Synact Pharma to present at the ABGSC Life Science Summit

Stockholm, Sweden — Synact Pharma AB ("SynAct" eller "Bolaget") today announces that the company will present at the ABGSC Life Science Summit on May 19, 2022. The company will be represented by **Chairman Dr. Torbjørn Bjerke**

The presentation will be available after the meeting on Synact Pharmas website; www.synactpharma.com.

The information was submitted, through the agency of the contact persons below, for publication on May 18, 2022.

For additional information, please contact:

Jeppé Øvlesen, CEO, +45 28 44 75 67, joo@synactpharma.com

Patrik Renblad, CFO, +46 707 47 97 68, par@synactpharma.com

SynAct in brief

SynAct Pharma AB conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. SynAct Pharma is listed on Spotlight Stock Market (ticker: SYNACT). For more information, please visit <https://synactpharma.com>.